QIAGEN plans to develop kits for the detection of CALR mutations
Share
Mutations of CALR have been discovered recently in an estimated 15% of cases of myeloproliferative neoplasms (MPNs - a group of blood disorders involving overproduction of blood cells) by the research team of Robert Kralovics at CeMM and collaboration partners at the Medical University of Vienna (NEJM doi: 10.1056/NEJMoa1311347). QIAGEN now licensed the technology from CeMM, and will develop a reliable diagnostic test for the CALR mutations offering each patient a clearer prognostic profile and guiding disease management. Development of a CALR diagnostic test will be highly complementary to QIAGEN’s kits for a key mutation of the Janus kinase 2 (JAK2) gene.